Caricamento...
RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer
Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKI), including gefitinib, provide a significant clinical benefit in non-small-cell lung cancer (NSCLC) patients, the acquisition of drug resistance has been known to limit the efficacy of EGFR-TKI therapy. In this stu...
Salvato in:
| Pubblicato in: | Cancer Sci |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Blackwell Publishing Ltd
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4317907/ https://ncbi.nlm.nih.gov/pubmed/24750242 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12425 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|